Symphogen is focused on developing antibody therapeutics primarily for oncology and immune oncology. The company utilizes an antibody discovery and research platform supported by early development capabilities.

Symphogen

Biotechnology

Innovation - Symphogen

mAb Mixtures and Cancer - Symphogen

Biotechnology Research

Partnering - Symphogen

Symphogen - Innovation

Symphogen | 12,112 followers on LinkedIn. Symphogen A/S, a Servier company and the Centre of Excellence for Antibodies, operates within in research, early clinical stages and CMC biologics development from research to market. Supporting Servier’s commitment to improve patients health and the R&amp;D strategy within oncology and immune-oncology - Symphogen’s  strategic focus is to apply our streamlined and effective antibody platform and capabilities in the discovery and early development of highly differentiated antibodies. The aim is to develop novel compounds either as combination or as stand-alone therapies for difficult to treat cancers.

Life science leadership professional; Process Development; Tech Transfer; Operational Excellence; CMO; Change Management; LEAN

Ronni Glenn Refstrup Hansen

Team Manager, Analytical Chemistry at Symphogen

Christian Glue

Principal scientist Symphogen A/S at Symphogen

Anne Worsaae

Birgitte Frost Tofthøj

We were honored to welcome Olivier Laureau and the Executive Committee to Symphogen , Servier ’s Antibody Center of Excellence, for a meaningful half-day visit. Our teams had the opportunity to showcase their expertise in monoclonal antibodies, resilience through challenging times, and commitment to Servier ’s mission to address unmet patient needs. As we expand from monoclonal antibodies into antibody-drug conjugates (ADCs) and bi-specifics, Symphogen is set to play a pivotal role in Servier ’s biologics pipeline. Over the next three years, we will strengthen our technological platforms, foster key partnerships, and evolve our ways of working to advance precision R&D. Our focus remains on leveraging digitalization, AI, and analytics, alongside building a balanced, flexible operating model that fosters global collaboration. Thank you to Olivier and the Executive Committee for the inspiring visit. Together, we’re driving forward the next generation of antibody therapeutics for patients worldwide. Olivier Laureau Damien Catoir Virginie Dominguez Hani Friedman Bouganim Philippe Gonnard David HINDLEY Arnaud Lallouette Pascal Lemaire Charlotte Marmousez - Tartar Stephane Mascarau Christophe Thurieau Olivier RUSSO Jerome Klein Claude Bertrand #RnD #innovation #WeAreServier #MovedByYou

We are hiring! Come join our innovative team to drive the development of cutting-edge therapeutic solutions. https://lnkd.in/dAjVy8_S

We are hiring! 3-year Postdoctoral position working with in-vivo imaging to study biodistribution of therapeutic antibodies and immune cells! Link: https://lnkd.in/dKkcq3wK

Are you the next candidate to join our exceptional analytical development team focused on therapeutic antibodies? We now have an unique Postdoctoral Position in Chromatography and Antibody-Drug-Conjugates (ADCs) Link: https://lnkd.in/dN5V4Vge

We had an incredible day at the OPUS 2024 Symphogen Annual Meeting! 🌟 The event was filled with inspiring discussions, starting with Christophe Thurieau and Olivier RUSSO , who shared their excitement about the future of biologics and highlighted how Symphogen ’s innovative strategies are driving continuous progress. We also had the pleasure of hearing from Malin Carlsson , Rikke Bolding Jensen , and Claus Haase, who reflected on our vision, objectives, and achievements—milestones that the entire organization takes great pride in. Adding to the energy, Sune Aggergaard , Thierry Dorval , Christian Skjødt , and Christophe Meyer delivered insightful talks on AI, clinical advancements, and much more, showcasing the brilliance of our teams at Symphogen and Servier . The focus of OPUS 2024 was clear: AI and DEI (Diversity, Equity, and Inclusion). We were captivated by Nikolaj Sonne , renowned tech expert and host of So ein Ding, who shared fascinating insights on artificial intelligence, exploring its real-world applications, challenges, and the evolving relationship between humans and machines—a truly inspiring session! Finally, a thought-provoking workshop led by Kasper Jelsbech from Living Institute reminded us of the power of recognizing and valuing each individual’s contributions, illustrating how DEI can significantly shape and strengthen our organization. A day full of learning, inspiration, and pride in what we’ve accomplished—and where we’re headed! #OPUS2024 #WeAreServier #MovedByYou #AI #Innovation #Technology #DiversityAndInclusion #UnconsciousBias #Teamwork

We are hiring! Are you a recent graduate and are you passionate about data and eager to kickstart your career? Do you want to transform data sets and develop algorithms to make raw data more useful? Come join our IT-Team to assist CMC Biologics and Research areas in creating innovative solutions. Link: https://lnkd.in/dQZZVZmX

We are hiring! Are you our new Team Manager, Purification? We are now offering a fantastic opportunity to join the Symphogen team. For more information: https://lnkd.in/dgjfBht6

We are hiring! Are you our new Drug Product Scientist? This is a unique opportunity to take part in the development of Symphogen’s antibody drug products. For more information: https://lnkd.in/d8YA2Kqk

news impact assignment basic	general
public peers	general	Nov 10, 2024 10:19 PM	ea1b05f7
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 10, 2024 10:19 PM	bd0ec1c3
crunchbase trigger	general	Nov 10, 2024 10:19 PM	0ae6cd74
crunchbase profile	general
li profile	general	Nov 10, 2024 10:19 PM	c1049ddf
translate crunchbase fundingrounds	general
peers	general	Nov 10, 2024 10:19 PM	2df64045
news basic	general	Nov 10, 2024 10:19 PM	d01b285d
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

SYMP

COM:SYMPHOGEN

Symphogen